{"brief_title": "D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients", "brief_summary": "To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.", "condition": "Neoplasms", "intervention_type": "Drug", "intervention_name": "dexmethylphenidate(d-mph)", "criteria": "- Diagnosis of cancer, excluding primary or metastatic brain tumors. - Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry. - Physical/neurological examination consistent with the absence of a focal neurological deficit - Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). - Subjects must be able to adhere to the protocol requirements. - Subjects must understand and voluntarily sign an informed consent document. - Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "id": "NCT00047476.xml"}